L
Luis M. Ruilope
Researcher at European University of Madrid
Publications - 891
Citations - 109166
Luis M. Ruilope is an academic researcher from European University of Madrid. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 94, co-authored 841 publications receiving 97778 citations. Previous affiliations of Luis M. Ruilope include Lund University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*
Pantelis Sarafidis,Alexandre Persu,Rajiv Agarwal,Michel Burnier,Peter W. de Leeuw,Charles J. Ferro,Jean-Michel Halimi,Gunnar H. Heine,Michel Jadoul,Faical Jarraya,Mehmet Kanbay,Francesca Mallamaci,Patrick B. Mark,Alberto Ortiz,Gianfranco Parati,Roberto Pontremoli,Patrick Rossignol,Luis M. Ruilope,Patricia Van der Niepen,Raymond Vanholder,Marianne C. Verhaar,Andrzej Wiecek,Grégoire Wuerzner,Gérard M. London,Carmine Zoccali +24 more
TL;DR: An overview of the diagnosis, epidemiology, pathogenesis and treatment of hypertension in patients on dialysis, aiming to offer the renal physician practical recommendations based on current knowledge and expert opinion and to highlight areas for future research.
Journal ArticleDOI
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luis M. Ruilope,Rajiv Agarwal,Stefan D. Anker,George L. Bakris,Gerasimos Filippatos,Christina Nowack,Peter Kolkhof,Amer Joseph,Nicole Mentenich,Bertram Pitt,Figaro-Dkd Investigators +10 more
TL;DR: The FIGARO-DKD trial will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
Journal ArticleDOI
Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study.
TL;DR: Night-time ABPM performed during treatment adds prognostic significance on the development of cardiovascular events in high-risk hypertensive patients, and among different ABPM-derived values, night-time SBP is the most potent predictor of outcome.
Journal ArticleDOI
Multiple Effects of Calcium Entry Blockers on Renal Function in Hypertension
TL;DR: There are reports indicating that calcium blockers are particularly effective in a subgroup of patients with essential hypertension who exhibit subtle but detectable alterations in calcium metabolism, which is proved to be effective for the treatment of essential hypertension with normal maintenance of renal function.
Journal ArticleDOI
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.
TL;DR: In this paper, the effects of renin-angiotensin system (RAS) blockade on renal endothelial function were analyzed in patients with type 2 diabetes, hypertension, glomerular filtration rate > 80 ml/min, and normo- or microalbuminuria.